Related Experiment Video
Updated: Jul 9, 2026

Removal of Trace Elements by Cupric Oxide Nanoparticles from Uranium In Situ Recovery Bleed Water and Its Effect on Cell Viability
Published on: June 21, 2015
Arsenic Plasma Concentrations and Methylation Efficiency as Key Factors of Arsenic Trioxide-Related Cardiac Toxicity
Meihua Guo1,2, Chenli Yue1,2, Yutong Liu1,2
1Department of Pharmacy, The First Affiliated Hospital of Harbin Medical University, Harbin, China.
Abstract:
Arsenic trioxide (ATO) is highly effective for acute promyelocytic leukemia (APL), but ATO-induced cardiac adverse events (CAEs) frequently cause treatment interruption or fatal outcomes, and real-world evidence linking arsenic species levels, methylation capacity, and CAE risk remains limited. In this study, we included 547 APL patients treated with ATO between 2014 and 2024 (4741 treatment cycles). Plasma concentrations of inorganic arsenic (iAs), monomethylated arsenic (MMA), and dimethylated arsenic (DMA) were measured in 374 patients using HPLC-HG-AFS. Primary (PMI = MMA/iAs) and secondary (SMI = DMA/MMA) methylation indices were calculated. Univariate and multivariate Cox regression identified independent CAE determinants, ROC analysis evaluated predictive values and cutoffs, and a risk nomogram was constructed. CAEs occurred in 297 patients (54.3%) and 554 treatment cycles (11.7%). Plasma arsenic distribution followed DMA, MMA > iAs, with PMI > SMI (all P < 0.05). Patients with CAEs had significantly higher DMA, iAs, total arsenic (tAs), and aberrant methylation profiles (all P < 0.05). Concomitant cardiotoxic drug use, DMA, tAs, SMI, DMA%, and MMA% were independent determinants. ROC analysis demonstrated good predictive performance for these markers (AUCs 0.708-0.869). The nomogram showed favorable discrimination (C-index = 0.823) and clinical net benefit. ECG abnormalities were the most common CAEs. ATO-induced cardiotoxicity is closely related to arsenic species concentration and methylation metabolism; importantly, impaired primary methylation (lower PMI, lower MMA%) appears to be the key bottleneck, with secondary methylation enhanced as a compensatory response (higher SMI, higher DMA%). Arsenic toxicokinetic and methylation markers effectively predict CAEs, supporting routine therapeutic drug monitoring in APL patients receiving ATO.
Related Concept Videos
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Drug Toxicity: Dose-Dependent Reactions
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Drug Toxicity: Risk factors
Anticholinesterase Agents: Poisoning and Treatment
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is slower than the...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

